Global Provenance
Exosomes sourced from the world's
most credible origins
Every product in our portfolio is sourced from manufacturers with established global track records — backed by peer-reviewed research, regulatory compliance, and thousands of documented clinical outcomes. ExoThera is the authorised distribution and advisory partner bringing these world-class solutions to Southeast Asia.
🇺🇸
United States
FDA-regulated manufacturers with peer-reviewed clinical data and research partnerships with Harvard and Yale.
🇨🇳
China
Leading biotech institutions at the forefront of exosome research, with large-scale clinical deployment across Asia.
🇰🇷
South Korea
Globally recognised aesthetics science hub with GMP-certified regenerative formulations and rigorous safety standards.
◈
Skin & Tissue Degeneration
Cellular turnover slows, collagen declines, and structural integrity weakens at the tissue level.
◈
Persistent Inflammation
Chronic low-grade inflammation disrupts normal repair signals and accelerates cellular ageing.
◈
Slower Healing
Recovery from injury, illness, and daily physiological stress takes longer as regenerative capacity diminishes.
◈
Fatigue & Reduced Vitality
Declining mitochondrial efficiency and systemic imbalance contribute to persistent fatigue and diminished energy.
◈
Joint & Musculoskeletal Discomfort
ECM degradation and reduced synovial support lead to progressive joint discomfort and restricted mobility.
The Regenerative Approach
Degeneration→Inflammation→Tissue Damage
Regenerative Signalling→Repair→Functional Support
Addressing the biological root of tissue degeneration helps reduce the risk of future pain and deterioration.
Why Exosomes?
A safer, cell-free approach
to regenerative medicine.
Unlike conventional approaches that suppress symptoms, exosome science supports the body's natural regenerative processes — delivering targeted biological signals at the cellular level.
Conventional Treatments
Symptom Control
Drugs & Surgery
Temporary Relief
Exosome Therapy
Tissue Repair Support
Biological Signalling
Regenerative Pathways
✓
Non-Immunogenic
Non-immunogenic — exosomes are cell-free vesicles that do not typically trigger immune rejection responses.
✓
Non-Tumorigenic
Non-tumorigenic — the cell-free formulation does not carry the differentiation risks associated with live cell therapies.
✓
No Live Cells
Pure signalling vesicles only — consistent, stable, and free from the variability of cellular therapies.
✓
Stem-Cell-Derived
Carries the regenerative signals of stem cells without the complexity or risk of stem cell administration.
✓
No Downtime
Individuals typically resume normal activity immediately — no recovery period or hospitalisation required.
✓
Surgery-Free
Administered via IV infusion or localised injection — minimally invasive and clinically straightforward.
01
Whole-Body IV Infusion
Exosomes circulate through the bloodstream to support recovery across the entire body — ideal for systemic conditions and general wellness.
Reduce inflammation
Boost recovery & support immunity
Support systemic recovery & physiological balance
Enhance overall wellness
02
Localised Injection (Targeted)
Targeted support for specific physiological systems. Exosome science explores the potential of directing regenerative signals to specific areas of the body.
Applicable Systems
NervousCardiovascularRespiratory
MusculoskeletalDermatologicHepatobiliary
ImmuneOphthalmologyReproductive
*Applications are under ongoing research and clinical evaluation.
Treatment suitability determined by a licensed medical professional.
Safe. Natural. Surgery-free.
Clinical Applications
Regenerative medicine
at cellular precision
MSC-derived exosome protocols for knee, spine and neurological applications, made available to licensed clinical partners and administered by their physicians following individual assessment. The information on this page is provided for research and educational purposes.
238+
Registered MSC clinical trials on the NIH database
MSC
Mesenchymal stem cell–derived exosomes — the basis of our protocols
3
Clinical application areas · Knee · Spine · Neurological
Areas of Clinical Interest
Knee ligament degeneration
Sports-related knee injuries
Post-surgical joint recovery
How MSC exosome therapy is understood to work in the knee
Mesenchymal stem cell–derived exosomes are nanoscale vesicles that carry proteins, microRNAs, and lipids from their parent stem cells. When delivered via intra-articular injection, research suggests they may act on two levels: helping to modulate the inflammatory cytokines (IL-1β, IL-6) associated with cartilage degradation, while supporting chondrocyte proliferation and extracellular matrix repair — the processes involved in rebuilding joint tissue.
Unlike corticosteroid injections, which are used for temporary pain relief, exosome therapy is being studied for its potential to address the underlying biology of joint degeneration. It is minimally invasive and typically involves minimal downtime.
Protocol structure
Step 01
Clinical Assessment
Assessment by the partner clinic’s physician, including imaging review, symptom history, and candidacy evaluation.
Step 02
Intra-Articular Injection
Single-session MSC exosome delivery into the knee joint, administered by the partner physician.
Step 03
Follow-Up & Monitoring
Post-procedure reviews to assess response, mobility, and comfort over time.
Treatment Comparison · Knee
Knee & Joint Pain — Treatment Comparison
Swipe to compare →
The Key Difference
Painkillers and injections work on the signal.
Exosome therapy works on the joint environment driving the wear.
When Surgery Is the Answer
An end-stage knee needs a surgeon. An earlier one may have room to work with, and an assessment shows which stage you are at.
Disclaimer: For general educational purposes only. Exosome-based therapies are investigational and subject to differing regulations across jurisdictions; human clinical research in osteoarthritis is ongoing. This is a simplified summary of published literature, manufacturer guidance and early clinical observations, and ratings are indicative, not clinical scores. It is not medical advice, a diagnosis or a recommendation for treatment, and no particular result is promised or guaranteed; individual responses vary. Suitability depends on the grade of osteoarthritis and must be assessed by a qualified physician. ExoThera and its partners accept no responsibility for outcomes arising from the use of this material.
Published Research · Knee
PubMed Central · Journal of Translational Medicine · Springer Nature · 2025
A randomised, double-blind, ascending-dose clinical study of human umbilical cord MSC-derived exosomes in osteoarthritis patients reported no adverse consequences, with clinical scoring and MRI examination indicating measurable cartilage improvement compared to baseline.
pmc.ncbi.nlm.nih.gov/articles/PMC12153132
PubMed Central · Frontiers in Pharmacology · Systematic Review & Meta-Analysis · 2025
A systematic review incorporating 28 preclinical studies found that MSC-derived exosomes were associated with cartilage repair outcomes across validated histological scoring systems (OARSI, Mankin, ICRS), reporting a statistically significant improvement in OA outcomes versus control (SMD = 7.20, p < 0.00001).
pmc.ncbi.nlm.nih.gov/articles/PMC12171193
PubMed Central · Frontiers in Bioengineering & Biotechnology · 2024
As of 2023, 238 registered clinical trials for MSC therapy in osteoarthritis are listed on the NIH database. MSC-derived exosomes share the therapeutic mechanisms of parent MSCs while avoiding the ethical and immunological limitations of cell transplantation.
frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2024.1331218
Areas of Research Interest
Vascular & Mixed Dementia
Cognitive decline & memory loss
Brain fog & executive function
Autism Spectrum (selected protocols)
Crossing the blood–brain barrier
The fundamental challenge in brain therapeutics is delivery: most compounds cannot cross the blood–brain barrier (BBB) in clinically meaningful quantities. MSC-derived exosomes are of interest here — their nanoscale size (30–150 nm) and lipid membrane composition are associated with transit across the BBB via natural transcytosis pathways, particularly the olfactory and trigeminal nerve routes enabled by intranasal administration.
Research in Neural Regeneration Research (2024) reports that intranasal delivery transports exosomes to the brain more effectively than intravenous injection alone for CNS indications. For broader cases, partner clinics may offer a combined format: intranasal administration, IV infusion, targeted injection, and an ongoing home-care programme.
Protocol formats
Intranasal Format
Single-route · intranasal delivery
- Neurological assessment by the partner physician
- MSC exosome intranasal administration
- Post-procedure follow-up
Combined Format
IV + injection + intranasal + home care
- Neurological assessment & profiling
- IV exosome infusion
- Targeted injection protocol
- Intranasal administration sessions
- Structured home-care programme
- Ongoing monitoring & review
Published Research · Neurological
Oxford Academic · Stem Cells Translational Medicine · 2020
Intranasal administration of MSC-derived extracellular vesicles in a triple-transgenic Alzheimer’s disease mouse model produced measurable immunomodulatory and neuroprotective effects, demonstrating the viability of intranasal EV delivery as a route for Alzheimer’s disease research. Cytokine-preconditioned MSC-EVs were reported to modulate neuroinflammation.
academic.oup.com/stcltm/article/9/9/1068/6406935
Neural Regeneration Research · LWW Journals · June 2024
A review of intranasal MSC exosome delivery in neurological conditions reported that the intranasal route — via olfactory and trigeminal nerve pathways — bypasses the blood–brain barrier and transports exosomes to the brain more effectively than intravenous injection for CNS indications, citing outcomes across Alzheimer’s, Parkinson’s, autism spectrum, and stroke models.
journals.lww.com/nrronline · Neural Regeneration Research 19(6), June 2024
PubMed Central · PMC11428860 · Systematic Review · 2024
A systematic review covering 99 articles — including 16 clinical studies and 16 ongoing clinical trials — described MSC-derived exosomes as a promising therapeutic candidate for Alzheimer’s disease, with mechanisms including reduction of β-amyloid accumulation, relief of neuronal damage, and alleviation of neuroinflammation and oxidative stress.
pmc.ncbi.nlm.nih.gov/articles/PMC11428860
PubMed Central · Journal of Translational Medicine · 2023
MSC-derived exosomes delivered to the striatum of Parkinson’s disease mouse models were associated with suppression of α-synuclein expression — a hallmark protein of PD pathology — and reduced dopaminergic neuronal death, indicating a neuroprotective effect in the disease’s primary affected brain region.
pmc.ncbi.nlm.nih.gov/articles/PMC10515429
Areas of Clinical Interest
Intervertebral disc degeneration
Sciatica & nerve compression
Degenerative disc disease
The biology of disc regeneration
The intervertebral disc is largely avascular, making it poorly responsive to the body’s natural repair mechanisms. MSC-derived exosomes introduced via injection to the affected disc space are understood to act through multiple pathways: supporting nucleus pulposus cell proliferation, helping regulate extracellular matrix balance, moderating pro-inflammatory cascades, and protecting against oxidative stress — all of which characterise disc degeneration.
A 2025 review in Wiley Advanced NanoBiomed Research describes exosomes exerting regenerative effects through ECM regulation, anti-inflammatory signalling, and cell-proliferation support — mechanisms that differ from those of current surgical and pharmacological options.
Protocol structure
Step 01
Clinical Assessment
Review of imaging (MRI / X-ray), symptom severity, and identification of affected disc levels by the partner physician.
Step 02
Spinal Injection
Precision delivery of MSC exosomes to the intervertebral disc space, administered by the partner physician.
Step 03
Follow-Up & Monitoring
Structured post-procedure reviews to assess comfort, function, and disc response over time.
Published Research · Spine
PubMed Central · International Journal of Molecular Sciences · 2022
A comprehensive review of MSC-derived exosomes in IVDD found that exosomes retain therapeutic properties of parent stem cells — paracrine signalling, ECM repair, immunomodulation — without risks associated with cell transplantation. Early studies described consistent promotion of cell proliferation and tissue regeneration in degenerated disc models.
pmc.ncbi.nlm.nih.gov/articles/PMC9267028
PubMed Central · Frontiers in Cell & Developmental Biology · 2022
MSC-derived exosomes are described as acting through differentiation, paracrine effects, and immunomodulation to facilitate extracellular matrix repair and reduce nucleus pulposus cell apoptosis — two primary mechanisms associated with intervertebral disc degeneration and lower back pain.
frontiersin.org/journals/cell-and-developmental-biology
Wiley Advanced NanoBiomed Research · 2025
A 2025 review of exosome-based approaches for IVDD described multi-mechanism regenerative action including ECM regulation, anti-inflammatory signalling, and cell-proliferation support, noting that exosomes from human umbilical cord MSCs preconditioned under hypoxia showed enhanced activity in disc tissue models.
advanced.onlinelibrary.wiley.com/doi/full/10.1002/anbr.202500074
For Clinical Partners
Partner Protocol Pack
available on request
Full protocol details are shared privately with licensed clinics and clinical collaborators who wish to work with ExoThera.
01
Protocol documentation
Knee, spine and neurological protocol structures, assessment criteria and follow-up schedules.
02
Partner terms
Partner pricing, suggested protocol values and the terms of working together.
03
Quality & governance
A Batch Quality Summary for every batch, with documented supply governance.
04
Storage & handling
Lyophilised format, ambient-stable at 2–30°C — no cold chain required.
Important Notice
For research and educational reference only. This page describes protocols that ExoThera makes available to licensed clinical partners; it is not an offer of treatment to the public. The areas of clinical and research interest listed above reflect published research and do not represent approved indications for any product. Research summaries are drawn from the cited peer-reviewed literature and do not describe results obtained with ExoThera products. Where offered, procedures are administered by licensed physicians at partner clinics following individual clinical evaluation, in accordance with applicable local regulations. ExoThera does not guarantee specific therapeutic outcomes.
